In‐office KTP laser treatment for laryngeal pathologies: 5‐years outcomes

Abstract

AbstractIntroductionIn the past two decades, laser systems were introduced into the office setting for laryngeal pathologies, offering the advantages of a shorter procedure and recovery. To date, long‐term data on outcomes is limited. This study aims to evaluate the efficacy and safety of the office‐based potassium‐titanyl‐phosphate (KTP) laser procedure for laryngeal pathologies.MethodsA retrospective cohort of in‐office KTP laser procedures for two main vocal folds lesions groups: (i) benign and pre‐malignant; and (ii) intraepithelial lesions in a prior invasive cancer field between 2010 and 2020. Data were collected from electronic medical records, telephone interviews, and video documentation of the procedure, including treatment completion, disease control, and whether additional interventions were required.ResultsA total of 81 patients underwent 153 in‐office KTP laser procedures for benign (36, 44.4%), pre‐malignant (15, 18.5%), and lesions in a prior malignancy field (30, 37.1%) with a mean of 1.89 ± 1.81 procedures per patient. One hundred and thirty‐eight (90.2%) procedures were well tolerated and completed successfully. During the 5‐years of follow‐up, 63% of the patients with previous malignancy were managed exclusively in the office. In the pre‐malignant group, 76% required no additional type of intervention. Patients with papilloma required significantly more procedures per patient compared with other pathologies (3.6 ± 4 vs. 1.61 ± 1, p‐value = 0.02). Surgery was required only in 18.2% of the papilloma patients. Three (1.9%) patients had short‐term complications, all resolved within 6 months. Failure to complete the procedure was significantly associated with active smoking (p‐value < 0.001) and, in most cases (90%), was related to patient intolerance.ConclusionOffice‐based KTP laser laryngeal procedures have shown promising results for both benign and selected cases of lesions in a prior malignancy field with a high compliance and a very low complication rate, suggesting its use as an effective and safe treatment modality for selected patients.